What's happening
This bill requires insurance companies in New York to cover monoclonal antibody treatment for COVID-19 under medical and prescription drug plans.
Why it matters
Ensures that insurance coverage for monoclonal antibody treatments for COVID-19 is on par with coverage for other COVID-19 treatments. , preventing insurers from making these treatments harder to access through higher out-of-pocket costs.
Prohibits insurance companies from manipulating policy terms or offering incentives to reduce access or discourage patients and doctors from using monoclonal antibody treatments. , aiming to protect patient choice and provider autonomy.
Prevents insurers from penalizing or financially influencing healthcare providers. regarding the recommendation or administration of monoclonal antibody treatments, reducing the risk of conflicts of interest that could impact patient care.
Blocks insurers from offsetting the new requirement by increasing patient costs for unrelated treatments. (like intravenous or injected anticancer medications), ensuring that patients don’t face new financial barriers elsewhere as a result of this mandate.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Cover Covid Antibody Treatment
Plain English, a few words. Used as the page title.
Sponsors
3 Co-sponsors
History
- Referred to insurance
- Referred to insurance
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
7076
2021-2022 Regular Sessions
IN ASSEMBLY
April 21, 2021
Introduced by M. of A. ABINANTI -- read once and referred to the Committee on Insurance
AN ACT to amend the insurance law, in relation to requiring insurance companies to provide coverage for monoclonal antibody treatment for the novel coronavirus (COVID-19)
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Subsection (i) of section 3216 of the insurance law is amended by adding a new paragraph 36 to read as follows:
(36) (A) Every policy delivered or issued for delivery in this state that provides medical, major medical, or similar comprehensive-type coverage and provides coverage for prescription drugs shall provide coverage for prescribed monoclonal antibody treatment for the novel coronavirus (COVID-19). Such coverage may be subject to co-pays, coinsurance or deductibles, provided that the co-pays, coinsurance or deductibles are at least as favorable to an insured as the co-pays, coinsurance or deductibles that apply to coverage for other treatments for the novel coronavirus (COVID-19).
(B) An insurer providing coverage under this paragraph and any participating entity through which the insurer offers health services shall not:
(i) vary the terms of the policy for the purpose or with the effect of avoiding compliance with this paragraph;
(ii) provide incentives (monetary or otherwise) to encourage a covered person to accept less than the minimum protections available under this paragraph;
(iii) penalize in any way or reduce or limit the compensation of a health care practitioner for recommending or providing care to a covered person in accordance with this paragraph;
(iv) provide incentives (monetary or otherwise) to a health care practitioner relating to the services provided pursuant to this paragraph
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD10737-01-1
A. 7076 2
intended to induce or have the effect of inducing such practitioner to provide care to a covered person in a manner inconsistent with this paragraph; or
(v) achieve compliance with this paragraph by imposing an increase in cost sharing for an intravenous or injected anticancer medication.
§ 2. Subsection (l) of section 3221 of the insurance law is amended by adding a new paragraph 21 to read as follows:
(21) (A) Every group or blanket policy delivered or issued for delivery in this state that provides medical, major medical, or similar comprehensive-type coverage and provides coverage for prescription drugs shall provide coverage for prescribed monoclonal antibody treatment for the novel coronavirus (COVID-19). Such coverage may be subject to co-pays, coinsurance or deductibles, provided that the co-pays, coinsurance or deductibles are at least as favorable to an insured as the co-pays, coinsurance or deductibles that apply to coverage for other treatments for the novel coronavirus (COVID-19).
(B) An insurer providing coverage under this paragraph and any participating entity through which the insurer offers health services shall not:
(i) vary the terms of the policy for the purpose or with the effect of avoiding compliance with this paragraph;
(ii) provide incentives (monetary or otherwise) to encourage a covered person to accept less than the minimum protections available under this paragraph;
(iii) penalize in any way or reduce or limit the compensation of a health care practitioner for recommending or providing care to a covered person in accordance with this paragraph;
(iv) provide incentives (monetary or otherwise) to a health care practitioner relating to the services provided pursuant to this paragraph intended to induce or have the effect of inducing such practitioner to provide care to a covered person in a manner inconsistent with this paragraph; or
(v) achieve compliance with this paragraph by imposing an increase in cost sharing for an intravenous or injected anticancer medication.
§ 3. Section 4303 of the insurance law is amended by adding a new subsection (ss) to read as follows:
(ss) (1) Every contract issued by a corporation subject to the provisions of this article that provides medical, major medical, or similar comprehensive-type coverage and provides coverage for prescription drugs shall provide coverage for prescribed monoclonal antibody treatment for the novel coronavirus (COVID-19). Such coverage may be subject to co-pays, coinsurance or deductibles, provided that the co-pays, coinsurance or deductibles are at least as favorable to an insured as the co-pays, coinsurance or deductibles that apply to coverage for other treatments for the novel coronavirus (COVID-19).
(2) An insurer providing coverage under this subsection and any participating entity through which the insurer offers health services shall not:
(A) vary the terms of the policy for the purpose or with the effect of avoiding compliance with this subsection;
(B) provide incentives (monetary or otherwise) to encourage a covered person to accept less than the minimum protections available under this subsection;
(C) penalize in any way or reduce or limit the compensation of a health care practitioner for recommending or providing care to a covered person in accordance with this subsection;
A. 7076 3
(D) provide incentives (monetary or otherwise) to a health care practitioner relating to the services provided pursuant to this subsection intended to induce or have the effect of inducing such practitioner to provide care to a covered person in a manner inconsistent with this subsection; or
(E) achieve compliance with this subsection by imposing an increase in cost sharing for an intravenous or injected anticancer medication.
§ 4. This act shall take effect on the ninetieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.